Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use

Current Eye Research

Volumn 32, Issue 4, 2007, Pages 345-352

  Salomão, Solange Rios ^a   Watanabe, Sung Eun Song ^a   Berezovsky, Adriana ^a   Motono, Marcia ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Breast cancer; Color vision; Electroretinography; Tamoxifen; Toxicity

Indexed keywords

TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CLINICAL ARTICLE; COLOR DISCRIMINATION; COLOR VISION; COLOR VISION DEFECT; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EYE EXAMINATION; EYE FUNDUS; EYE TOXICITY; FEMALE; HUMAN; KERATOPATHY; PRIORITY JOURNAL; RETINA; RETINOPATHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COLOR PERCEPTION; COLOR PERCEPTION TESTS; ELECTRORETINOGRAPHY; EYE DISEASES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RETINA; TAMOXIFEN;

EID: 34247354550     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701229638     Document Type: Article

References (31)

1. Brasil. Ministério da Sáude. Secretaria de Atenção à Saúde. Instituto Nacional de Câncer. Coordenação de Prevenção e Vigilância. Estimativa 2006: Incidência de Câncer no Brasil. Rio de Janeiro: INCA; 2005:25-31.
2. Robles SC, Galanis E. Breast cancer in Latin America and the Caribbean. Pan Am J Public Health. 2002;11:178-184.
3. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371-1388.
4. Osborn CK. Drug therapy: tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618.
5. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer. 2004;11:391-406.
6. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
7. Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr. 2001;30:56-61.
8. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315-320.
9. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that longterm, low-dose tamoxifen treatment can induce ocular toxicity. Cancer. 1992;69:2961-2964.
10. Noureddin BN, Seoud M, Bashshur Z, et al. Ocular toxicity in low-dosage tamoxifen: a prospective study. Eye. 1999;13:729-733.
11. Gorin MB, Day R, Constantino JP, et al. Long term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493-501.
12. Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res. 2000;60:167-172.
13. Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol. 1994;117:772-775.
14. Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye. 1997;11:295-297.
15. Lazzaroni F, Scorolli L, Pizzoleo CF, et al. Tamoxifen retinopathy: does it really exist? Graefes Arch Clin Exp Ophthalmol. 1998;236:669-673.
16. Ashford AR, Donev I, Tiwari RP, Garrett TJ. Reversible ocular toxicity related to tamoxifen therapy. Cancer. 1988;61:33-35.
17. Eisner A, Austin DF, Samples JR. Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol. 2004;88:125-130.
18. Eisner A, O'Malley JP, Incognito LJ, Toomey MD. Small optic disk cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy. Curr Eye Res. 2006,31:367-379.
19. Eisner A, Incognito LJ. The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen. Vis Res. 2006;46:1816-1822.
20. Flaxel CJ, Mulholland B, Haynes B, Gregor ZJ. Intraocular penetration of tamoxifen. Ophthalmology 2000;107:2006-2009.
21. Parkkari M, Paakkala A-M, Salminen L, Holli K, Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand. 2003;81:495-499.
22. Kuchenbecker J, Pump-Schmidt C, Olbricht S, et al. Elektrophysiologische Untersuchungen bei Mammakarzinompatientinnenmit Tamoxifen-Retinopathie. Ophthalmologe. 2001;98:81-85.
23. Dawson WW, Jordan BL, Marsh RD, et al. Distant cancer effects on standardized testing of peripheral vision. Br J Ophthalmol. 2001;85:291-296.
24. Sadowski B, Kriegbaum C, Apfelstedt-Sylla E. Tamoxifen side effects, age-related macular degeneration (AMD) or cancer associated retinopathy (CAR)? Eur J Ophthalmol. 2001;11:309-312.
25. Verriest G, Laethem TH, Uvijls A. A new assessment of the normal ranges of the Farnsworth-Munsell 100-hue test scores. Am J Ophthalmol. 1982;93:635-642.
26. Sutter EE. Imaging visual function with the multifocal m-sequence technique. Vis Res. 2001;41:1241-1255.
27. Berezovsky A, Pereira JM, Sacai PY, et al. Physiological loss of retinal central function assessed by multifocal electroretinogram [abstract]. Invest Ophthalmol Vis Sci. 2005;46:E-abstract 3435.
28. Maturi RK, Minzhong Y, Weleber RG. Multifocal electroretinography evaluation of long-term hydroxichloroquine users. Arch Ophthalmol. 2004;122:973-981.
29. Ventura DF, Costa MT, Costa MF, et al. Multifocal and full-field electroretinogram changes associated with color-vision loss in mercury vapor exposure. Vis Neurosci. 2004;21:421-429.
30. Kaiser-Kupfer MI, Kupfer C, Rodrigues M. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology. 1981;88:89-93.
31. Hood DC. Assessing retinal function with the multifocal technique. Prog Ret Eye Res. 2000;19:607-646.